These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 26512778)

  • 1. Ki67/SATB1 ratio is an independent prognostic factor of overall survival in patients with early hormone receptor-positive invasive ductal breast carcinoma.
    Laurinavicius A; Green AR; Laurinaviciene A; Smailyte G; Ostapenko V; Meskauskas R; Ellis IO
    Oncotarget; 2015 Dec; 6(38):41134-45. PubMed ID: 26512778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemistry profiles of breast ductal carcinoma: factor analysis of digital image analysis data.
    Laurinavicius A; Laurinaviciene A; Ostapenko V; Dasevicius D; Jarmalaite S; Lazutka J
    Diagn Pathol; 2012 Mar; 7():27. PubMed ID: 22424533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of SATB1 protein in the ductal breast carcinoma tissue microarrays - preliminary study.
    Kobierzycki C; Wojnar A; Dziegiel P
    Folia Histochem Cytobiol; 2013; 51(4):333-8. PubMed ID: 24497139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High Ki67/BCL2 index is associated with worse outcome in early stage breast cancer.
    Min KW; Kim DH; Do SI; Pyo JS; Chae SW; Sohn JH; Kim K; Lee HJ; Kim DH; Oh S; Choi SH; Park YL; Park CH; Kwon MJ; Moon KM
    Postgrad Med J; 2016 Dec; 92(1094):707-714. PubMed ID: 27222586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of SATB1 and HER2 in breast cancer and the correlations with clinicopathologic characteristics.
    Liu X; Zheng Y; Qiao C; Qv F; Wang J; Ding B; Sun Y; Wang Y
    Diagn Pathol; 2015 May; 10():50. PubMed ID: 25956130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypoxia-inducible factor 1alpha is closely linked to an aggressive phenotype in breast cancer.
    Yamamoto Y; Ibusuki M; Okumura Y; Kawasoe T; Kai K; Iyama K; Iwase H
    Breast Cancer Res Treat; 2008 Aug; 110(3):465-75. PubMed ID: 17805961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bimodality of intratumor Ki67 expression is an independent prognostic factor of overall survival in patients with invasive breast carcinoma.
    Laurinavicius A; Plancoulaine B; Rasmusson A; Besusparis J; Augulis R; Meskauskas R; Herlin P; Laurinaviciene A; Abdelhadi Muftah AA; Miligy I; Aleskandarany M; Rakha EA; Green AR; Ellis IO
    Virchows Arch; 2016 Apr; 468(4):493-502. PubMed ID: 26818835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIF-1alpha and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome.
    Trastour C; Benizri E; Ettore F; Ramaioli A; Chamorey E; Pouysségur J; Berra E
    Int J Cancer; 2007 Apr; 120(7):1451-8. PubMed ID: 17245699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical investigation of the angiogenic proteins VEGF, HIF-1α and CD34 in invasive ductal carcinoma of the breast.
    Maschio LB; Madallozo BB; Capellasso BA; Jardim BV; Moschetta MG; Jampietro J; Soares FA; Zuccari DA
    Acta Histochem; 2014 Jan; 116(1):148-57. PubMed ID: 23899963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of Hypoxia-Inducible Factor 1α in Invasive Breast Cancer with Metastasis to Lymph Nodes: Correlation with Steroid Receptors, HER2 and EPO-R.
    Badowska-Kozakiewicz A; Sobol M; Patera J
    Adv Clin Exp Med; 2016; 25(4):741-50. PubMed ID: 27629849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of tumor hypoxia in MUC1-positive breast carcinomas.
    Zanetti JS; Soave DF; Oliveira-Costa JP; da Silveira GG; Ramalho LN; Garcia SB; Zucoloto S; Ribeiro-Silva A
    Virchows Arch; 2011 Oct; 459(4):367-75. PubMed ID: 21892751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of geminin expression levels in Ki67-high subset of estrogen receptor-positive and HER2-negative breast cancers.
    Yagi T; Inoue N; Yanai A; Murase K; Imamura M; Miyagawa Y; Enomoto Y; Nishimukai A; Takatsuka Y; Hirota S; Akazawa K; Miyoshi Y
    Breast Cancer; 2016 Mar; 23(2):224-30. PubMed ID: 25082658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer.
    Milde-Langosch K; Karn T; Müller V; Witzel I; Rody A; Schmidt M; Wirtz RM
    Breast Cancer Res Treat; 2013 Jan; 137(1):57-67. PubMed ID: 23135572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer.
    Ali HR; Dawson SJ; Blows FM; Provenzano E; Leung S; Nielsen T; Pharoah PD; Caldas C
    J Pathol; 2012 Jan; 226(1):97-107. PubMed ID: 21953021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups.
    Abubakar M; Orr N; Daley F; Coulson P; Ali HR; Blows F; Benitez J; Milne R; Brenner H; Stegmaier C; Mannermaa A; Chang-Claude J; Rudolph A; Sinn P; Couch FJ; Devilee P; Tollenaar RA; Seynaeve C; Figueroa J; Sherman ME; Lissowska J; Hewitt S; Eccles D; Hooning MJ; Hollestelle A; Martens JW; van Deurzen CH; ; Bolla MK; Wang Q; Jones M; Schoemaker M; Wesseling J; van Leeuwen FE; Van 't Veer L; Easton D; Swerdlow AJ; Dowsett M; Pharoah PD; Schmidt MK; Garcia-Closas M
    Breast Cancer Res; 2016 Oct; 18(1):104. PubMed ID: 27756439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proliferative Index (Ki67) for Prediction in Breast Duct Carcinomas.
    Ahmed ST; Ahmed AM; Musa DH; Sulayvani FK; Al-Khyatt M; Pity IS
    Asian Pac J Cancer Prev; 2018 Apr; 19(4):955-959. PubMed ID: 29693354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma.
    Bos R; van der Groep P; Greijer AE; Shvarts A; Meijer S; Pinedo HM; Semenza GL; van Diest PJ; van der Wall E
    Cancer; 2003 Mar; 97(6):1573-81. PubMed ID: 12627523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Independent Prognostic Value of Intratumoral Heterogeneity and Immune Response Features by Automated Digital Immunohistochemistry Analysis in Early Hormone Receptor-Positive Breast Carcinoma.
    Zilenaite D; Rasmusson A; Augulis R; Besusparis J; Laurinaviciene A; Plancoulaine B; Ostapenko V; Laurinavicius A
    Front Oncol; 2020; 10():950. PubMed ID: 32612954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expressions of individual PHDs associate with good prognostic factors and increased proliferation in breast cancer patients.
    Peurala E; Koivunen P; Bloigu R; Haapasaari KM; Jukkola-Vuorinen A
    Breast Cancer Res Treat; 2012 May; 133(1):179-88. PubMed ID: 21877141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.